

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Chait 1



Section 1.	Identifying Inform	ation				
1. Given Name (First Name) Alan		2. Surname (Last Name) 3. Date Chait 20-February-2019				
4. Are you the cor	esponding author?	✓ Yes No				
5. Manuscript Title		MOST OFTEN MUL	ΓΙFACTORIAL: Α ΝΑ	ARRATIVE	REVIEW OF CAUSES AND TREATMENT	
6. Manuscript Ider M19-0203	itifying Number (if you kn	ow it)				
Section 2.	The Work Under Co	onsideration for I	Publication			
any aspect of the s statistical analysis,	ubmitted work (including	but not limited to gra			ent, commercial, private foundation, etc.) for udy design, manuscript preparation,	
Section 3.	Relevant financial a	activities outside	the submitted	work.		
of compensation) with entities as descri	bed in the instruction	ons. Use one line fo	or each en	ial relationships (regardless of amount atity; add as many lines as you need by a 36 months prior to publication .	
_	evant conflicts of intere		No	-		
If yes, please fill o	out the appropriate info	rmation below.				
Name of Entity		Grant? Persona Fees?	Non-Financial Support?	Other?	Comments	
Medimmune		✓			Consultation and grant unrelated to this paper	
onis					Consultation	
Section 4.	Intellectual Proper	ty Patents & Co	pyrights			
Do you have any	patents, whether planr	ned, pending or issu	ed, broadly releva	nt to the	work? Yes V	

Chait 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Chait reports	grants and personal fees from Medimmune, personal fees from Ionis, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Chait 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Identifying Information

Section 1.

ICMJE Form for Disclosure of Potential Conflicts of Interest

1. Given Name (First Name) Robert H.	2. Surnai Eckel	me (Last Nar	ne)		3. Date 04-February-2019
4. Are you the corresponding author?	Yes	√ No	Correspond Paula Holl	_	
5. Manuscript Title Physical Activity Improves Lipid and We Obesity	eight Loss	Outcomes	Post-Metabolic B	Bariatric S	urgery in Adolescents with Severe
6. Manuscript Identifying Number (if you kn	ow it)				
Section 2. The Work Under Co	onsidera	tion for P	ublication		
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)?					
Are there any relevant conflicts of intere	st?	Yes 🗸	No		
Section 3. Relevant financial	activities	s outside 1	the submitted	work.	
Place a check in the appropriate boxes in of compensation) with entities as descriclicking the "Add +" box. You should rep	bed in the	instruction	ns. Use one line fo	or each er	ntity; add as many lines as you need by
Are there any relevant conflicts of intere			No		
If yes, please fill out the appropriate info	rmation t	eiow.			
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
NINDS	✓				R21 - Multiple Sclerosis Funding
NIA	✓				R21 - Alzheimer's Disease Funding
NHLBI	✓				T32 PI
onis Pharmaceutical	✓				Post-heparin plasma LPL assays
Jniqure Biopharma	✓				Post-heparin plasma LPL assays
CTSA Pilot Project	✓				Microglial LPL and MS
Endece, LLC	✓				NDC-1308 KDB2 mechanism of action
Cardiometabolic Health Congress		✓			Co-chair



Name of Entity	Grant	Fees?	Support?	Other •	Comments
Prime		√			CME
Medtelligence		✓			CME
Medscape		√			CME
Medical Education Resources		✓			CME
Vox Media		✓			CME
Sanofi/Regeneron		✓			Advisory Board, Expert Witness
Merck		✓			Advisory Board
Novo Nordisk		✓			Advisory Board
Kowa		✓			Prominent Clinical Trial Scientific Commttee
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo					
Section 5. Relationships not	covered	above			
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?					
Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest					
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.					

Personal Non-Financial

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Eckel reports grants from NINDS, grants from NIA, grants from NHLBI, grants from Ionis Pharmaceutical, grants from Uniqure Biopharma, grants from CTSA Pilot Project, grants from Endece, LLC, personal fees from Cardiometabolic Health Congress, personal fees from Prime, personal fees from Medtelligence, personal fees from Medscape, personal fees from Medical Education Resources, personal fees from Vox Media, personal fees from Sanofi/Regeneron, personal fees from Merck, personal fees from Novo Nordisk, personal fees from Kowa, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.